Market Leadership Fziomed is a global leader in postsurgical adhesion prevention with nearly one million patients treated worldwide since 2002, demonstrating a strong track record and credibility that can facilitate outreach to major surgical centers and healthcare providers.

Product Innovation The company's proprietary synthetic dual-polymer technology and tailored adhesion barrier gels across various surgical applications highlight opportunities to engage hospitals and clinics seeking advanced, patented solutions to improve patient outcomes.

Recent Recognition Being recognized as one of the Best Places to Work in Southern California for three consecutive years indicates a positive company culture, which can be leveraged when positioning Fziomed as a preferred partner for strategic collaborations and distribution channels.

Growth & Expansion With a revenue estimate between $50 million and $100 million and active participation in industry events like the 2025 IFSSH and IFSHT Congress, Fziomed presents ongoing opportunities to expand market presence in key surgical segments worldwide.

Leadership & Talent Recent high-level appointments of industry veteran leaders as President, CEO, and Board members suggest a strategic focus on innovation and growth, making Fziomed an appealing partner for collaborations aimed at leveraging advanced surgical biomaterials.